Regeneron committed $125 million to Parabilis Medicines upfront: $50 million in cash and a $75 million pledge toward the biotech’s next financing round, in a collaboration worth up to $2.3 billion if milestones and royalties pay out.
The structure echoes how large pharma has handled early-stage ADC platform bets: modest upfront, option chain locked in, backend milestones carrying the bulk of the value. AstraZeneca’s 2019 deal with Daiichi Sankyo on Enhertu used the same blueprint. Parabilis is at an earlier stage than Daiichi was, and Regeneron can add more targets for additional payments, making this a de facto call option on Parabilis’ platform.
What does Regeneron actually get? Access to Parabilis’ Helicon platform: engineered peptides that penetrate cells and bind to intracellular protein targets that traditional small molecules can’t reach. The goal is to pair Helicon payloads with Regeneron’s antibody-drug conjugate delivery system to create antibody-helicon conjugates (AHCs), a drug class that doesn’t exist yet. Five initial targets are on the agenda, with Regeneron responsible for development, manufacturing, and commercialization downstream.
Parabilis, formerly FogPharma, raised a $305 million Series F earlier this year for lead asset zolucatetide, an investigational peptide therapy being tested for rare and solid tumors. That program isn’t part of this collaboration; AHCs are a separate bet.
The announcement landed on a bad Monday for Regeneron: the company’s LAG-3 inhibitor failed in first-line melanoma against Merck’s Keytruda, sending the stock down more than 10%. BMO Capital Markets called it “the defining catalyst of 1H26” — a miss that puts “even more pressure” on Regeneron’s pipeline. Whether AHCs can carry the pipeline now is Regeneron’s $2.2 billion question.
— Diana Kowalski